Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
PEACE-3 demonstrates that combining enzalutamide with Ra223 as first-line therapy for mCRPC significantly improves rPFS. Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis.
Authors
- F Gómez Veiga
- Thierry Roumeguère (ORCID: https://orcid.org/0000-0002-5377-8137)
- Pedro Isaacsson Velho (ORCID: https://orcid.org/0000-0002-3117-7031)
- Ray McDermott (ORCID: https://orcid.org/0000-0002-8952-4315)
- Coralie Poncet (ORCID: https://orcid.org/0000-0002-8635-9350)
- Bertrand F. TOMBAL (ORCID: https://orcid.org/0000-0002-0093-8408)
- A. Rodriguez-Vida (ORCID: https://orcid.org/0000-0002-2518-485X)
- Yohann Loriot (ORCID: https://orcid.org/0000-0002-8338-1739)
- Andrey Soares (ORCID: https://orcid.org/0000-0003-4980-6729)
- Felipe José Silva Melo Cruz (ORCID: https://orcid.org/0000-0002-4558-4850)
- Corneel Coens (ORCID: https://orcid.org/0000-0001-7601-5450)
- Pablo Maroto (ORCID: https://orcid.org/0000-0002-0030-0412)
- Frederic E. Lecouvet (ORCID: https://orcid.org/0000-0003-3568-3254)
- Ananya Choudhury (ORCID: https://orcid.org/0000-0002-3561-6580)
- Gedske Daugaard (ORCID: https://orcid.org/0000-0002-9618-9180)
- Flavio Mavignier Cárcano (ORCID: https://orcid.org/0000-0002-0002-3507)
- Farid Saad (ORCID: https://orcid.org/0000-0002-0449-6635)
- S. Gillessen
- Karine Martins da Trindade (ORCID: https://orcid.org/0009-0006-4947-0304)
- Iwona Skoneczna
- Rosely Yamamura (ORCID: https://orcid.org/0000-0002-2823-7910)
- Emmanuelle Bompas (ORCID: https://orcid.org/0000-0003-4414-7760)
- Franco Nolè (ORCID: https://orcid.org/0000-0002-4326-7544)
- E. Gallardo
- B. Fournier
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- Universidad de Salamanca (ES)
- Université Paris-Saclay (FR)
- Hospital Israelita Albert Einstein (BR)
- Hospital de Sant Pau (ES)
- Institut Gustave Roussy (FR)
- Erasmus Hospital (BE)
- Rigshospitalet (DK)
- Tallaght University Hospital (IE)
- Hospital Moinhos de Vento (BR)
- Hospital de Câncer de Barretos (BR)
- D’Or Institute for Research and Education (BR)
- Institut de Cancérologie de l'Ouest (FR)
- Beneficência Portuguesa de São Paulo (BR)
- European Organisation for Research and Treatment of Cancer (BE)
- Hospital Del Mar (ES)
- The Christie NHS Foundation Trust (GB)
- Institute of Research and Innovation Parc Tauli (ES)
- Centre Hospitalier de l’Université de Montréal (CA)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Instituto Brasileiro de Controle do Câncer (BR)
- Università della Svizzera italiana (CH)
- European Institute of Oncology (IT)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1016/j.annonc.2025.05.011
- Citations
- 28
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 42.51
Funders
- Astellas Pharma US
- Bayer
- Bayer HealthCare
- Astellas Pharma
- Astellas Pharma Europe